Annotating MYC Status in Treatment-Resistant Metastatic Castration-Resistant Prostate Cancer with Gallium-68 Citrate PET

Abstract

We are the first group to clinically investigate transferrin-based PET imaging in advanced prostate cancer with the use of gallium citrate PET as a non-invasive imaging biomarker of MYC activity. To date, we have successfully completed 40 whole body gallium citrate PET scans in 30 patients. 10 of the 30 patients enrolled have completed paired baseline and post treatment initiation scans following treatment with either BET bromodomain inhibition or other standard of care therapies. We have successfully completed the interim analysis demonstrated acceptable safety of the imaging tracer and preliminary evidence of the diagnostic and predictive utility of gallum citrate PET in abiraterone-resistant metastatic castration resistant prostate cancer (mCRPC).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2018
Accession Number
AD1064859

Entities

People

  • Rahul Aggarwal

Organizations

  • University of California, San Francisco

Tags

DTIC Thesaurus Topics

  • Acquisition
  • Amplification
  • Biological Markers
  • Biomedical Research
  • Castration
  • Clinical Trials
  • Data Analysis
  • Department Of Defense
  • Governments
  • Inhibition
  • Inhibitors
  • Institutional Review Board
  • Local Governments
  • Medical Personnel
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Standards
  • Statistical Analysis
  • Targets
  • Therapy
  • Time Intervals
  • Tissues

Fields of Study

  • Medicine
  • Physics

Readers

  • Medical Imaging.
  • Oncology
  • Prostate Cancer Biology.

Technology Areas

  • Microelectronics